This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dotzlaw, H. Articles by C. Murphy, L. Search for Related Content PubMed PubMed Citation Articles by Dotzlaw, H. Articles by C. Murphy, L.

The Human Orphan Receptor PXR Messenger RNA Is Expressed in Both Normal and Neoplastic Breast Tissue¹

Departments of Biochemistry and Molecular Biology [H. D., E. L., L. C. M.] and Pathology [P. W.], University of Manitoba, Winnipeg, Manitoba, Canada R3E 0W3

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The expression of PXR mRNA and a variant PXR mRNA, deleted in 111 nucleotides in the ligand-binding domain, was detected by reverse transcription-PCR amplification in both normal and neoplastic human breast tissues. The level of PXR mRNA did not differ between breast tumors and their adjacent matched normal breast tissues. However, the expression of PXR mRNA did vary among breast tumors. A statistically significant inverse relationship was found between the level of PXR mRNA expression and estrogen receptor (ER) status, as defined by ligand binding analysis. The level of PXR mRNA expression in ER+ tumors (median = 22.4, n = 15) was significantly lower (P = 0.04) than the level of PXR mRNA expression in ER- tumors (median = 46.7, n = 15). No relationship with progesterone receptor status was found. These data raise the possibility that PXR has a role in human breast tissues.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
A novel orphan receptor, PXR, activated by pregnanes, was originally cloned from a mouse liver cDNA library (1) . Its human "homologue," hPXR, has been recently cloned from a human liver cDNA library (2) . This orphan receptor can be activated by natural and synthetic pregnenolone derivatives as well as the antiglucocorticoid/antiprogestin RU-486. A possible target gene of hPXR is CYP3A,³ which is thought to have a role in the biotransformation of many drugs (2) . Also, the CYP3A enzymes have been implicated as major players in the metabolism of the clinically useful antiestrogens tamoxifen and toremifene (3, 4, 5) . Although the major site of expression of hPXR and CYP3A enzymes is the liver, CYP3A enzymes have also been found in human breast cancer tissue (6 , 7) . Because these enzymes are involved in the metabolism of several antihormonal agents used in the treatment of breast cancer and because their potential transcriptional regulator, hPXR, can be activated by another endocrine agent (i.e., RU-486), we considered the possibility that the presence of such a pathway in breast cancers may have an influence on the efficacy of some endocrine therapies. To determine the potential existence of such a pathway in human breast cancer, we have investigated the expression of hPXR mRNA in both normal and neoplastic human breast tissue.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Materials
All cell culture reagents were obtained from Life Technologies, Inc. (Burlington, Ontario, Canada). [-³²P]dCTP was purchased from ICN (Montreal, Quebec, Canada).

Human Breast Tissues
Thirteen cases were selected from the NCIC-Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada). For each case, matched adjacent normal and tumor frozen tissue blocks were available. The quality of each block was determined by the histopathological assessment of sections from adjacent mirror image paraffin-embedded tissue blocks, as described previously (8) . The presence of normal ducts and lobules and the absence of any atypical lesion were confirmed in all normal tissue specimens. Histopathological analysis was performed on H&E-stained sections from the paraffin tissue block to estimate, for each case, the proportions of tumor and normal epithelial cells, fibroblasts, and fat as well as to determine the levels of inflammation and Nottingham grade scores. Six tumors were ER- (ER < 3 fmol/mg protein), with PR values ranging from 4.9 to 11.2 fmol/mg protein, as measured by ligand binding assay. Seven tumors were ER+ (ER values ranging from 3.5 to 134 fmol/mg protein), with PR values ranging from 5.8 to 134 fmol/mg protein. These tumors spanned a wide range of grade (grade 5–9), determined using the Nottingham grading system.

In a second experiment, 40 invasive ductal breast carcinomas were selected from the NCIC-Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada). The cases were selected for ER and PR status, as determined by ligand binding assays. Ten tumors were classified as ER+/PR+ (ER range, 50–127 fmol/mg protein; PR range, 105–285 fmol/mg protein), 10 tumors were classified as ER+/PR- (ER range, 59–156 fmol/mg protein; PR range, 5–10 fmol/mg protein), 10 tumors were ER-/PR- (ER range, 0–2 fmol/mg protein; PR range, 0–10 fmol/mg protein), and 10 tumors were classified as ER-/PR+ (ER range, 5–9 fmol/mg protein; PR range, 51–271 fmol/mg protein).

Ligand Binding Assays for ER and PR
Available steroid receptors were assayed using a single saturating dose of [³H]ligand plus 500-fold excess of unlabeled ligand and incubated overnight at 4°, and the bound and free steroids were separated using the charcoal-dextran method. ER and PR concentrations were expressed as fmol of steroid specifically bound per mg of cytosol protein, as described previously (9) .

Cell Culture
Human breast cancer cells were grown in DMEM supplemented with 5% fetal bovine serum, 100 nM glutamine, 0.3% (v/v) glucose, and penicillin/streptomycin, as described previously (10) . The cells were grown until they were 80% confluent, and they were harvested by scraping with a rubber policeman. After centrifugation, the cell pellet was frozen and stored at -70° until RNA was isolated.

RNA Extraction and RT-PCR conditions
Total RNA was extracted from 20-µm frozen tissue sections (15 and 5 sections for normal and tumor breast tissue, respectively) or frozen cell pellets using Trizol reagent (Life Technologies, Inc., Grand Island, NY), according to the manufacturer’s instructions. One µg of total RNA was reverse-transcribed in a final volume of 25 µl, as described previously (11) .

The primers used consisted of hPXR-U primer (sense, 5'-CAAGCGGAAGAAAAGTGAACG-3'; nucleotides 678–698 of hPXR) and hPXR-L primer (antisense, 5'-CTGGTCCTCGATGGGCAAGTC-3'; nucleotides 1119–1099 of hPXR). The nucleotide positions given correspond to published sequences of the human PXR cDNA (2) . PCR amplifications were performed, and PCR products were analyzed as described previously, with modifications (11) . Briefly, 1 µl of reverse transcription mixture was amplified in a final volume of 15 µl, in the presence of 1.5 µCi of [-³²P]dCTP (3000 Ci/mmol), 4 ng/µl hPXR-U/hPXR-L, and 0.4 unit of Hot Start Taq DNA polymerase (Qiagen, Mississauga, Ontario, Canada). Each PCR consisted of 20 min at 95°, followed by 35 cycles of 30 s at 94°, 30 s at 60°, and 30 s at 72°. PCR products were then separated on 6% polyacrylamide gels containing 7 M urea. Following electrophoresis, the gels were dried and autoradiographed. Amplification of the ubiquitously expressed GAPDH cDNA was performed in parallel, and PCR products were separated on agarose gels stained with ethidium bromide, as described previously (11) . PCR products were subcloned and sequenced as described previously (11) .

Quantification and Statistical Analysis
Quantification of signals was carried out by excision of the bands corresponding to hPXR cDNAs (wild-type and variant cDNAs), addition of scintillant, and counting. Three independent PCRs were performed. To control for variations between experiments, a value of 100% was assigned to the sum of hPXR-related signals (wild-type plus variant, when present) measured in one of the tumor samples arbitrarily chosen (case 1) and used as the reference in all individual PCR assays. For each sample, the sum of hPXR-related signals (wild-type plus variant, when present) was expressed as the percentage of the case 1 value. In parallel, GAPDH cDNA was amplified, and following analysis of PCR products on prestained agarose gels, signals were quantified by scanning using NIH Image 161/ppc software. Two independent GAPDH PCRs were performed. Each GAPDH signal was also expressed as a percentage of the GAPDH value measured in case 1. For each sample, the average of the hPXR values was then expressed as a percentage of the average of the GAPDH signals. Only samples (n = 13 for the tumor and matched normal experiment; n = 30 for the ER/PR tumor experiment), which demonstrated a reproducible wild-type hPXR signal (present or absent, see "Results"), were included in the statistical analysis. Differences in hPXR mRNA expression between groups were tested using the Mann-Whitney rank sum test (two-sided).

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Expression of hPXR mRNA and a Variant hPXR mRNA in Human Breast Cancer Cell Lines
A RT-PCR approach was used to determine whether mRNA for hPXR was expressed in human breast cancer cell lines. In several human breast cancer cell lines, an expected 442-bp product was detected in T-47D, MCF-7, T-47D-5, and MDA-MB-231 but not in BT20 or MDA-MB-468 human breast cancer cells (Fig. 1) . The ER- MDA-MB-231 cell line expressed the highest level of hPXR mRNA. However, the expression of hPXR mRNA was not related to the absolute ER status of the cell line in this small set of cell lines because both ER+ (T-47D and MCF-7) and ER- (MDA-MB-231) cells expressed hPXR mRNA. In some cell lines (T-47D-5 and MDA-MB-231), a smaller-sized PCR product of 331 bp was observed. Both of these PCR products were cloned and sequenced. The larger 442-bp product had a nucleotide sequence that was identical to that previously published for the human PXR cDNA (2) . The 331-bp product was deleted in 111 nucleotides, which correspond to nucleotides 823–933 of the hPXR cDNA, as numbered in Lehmann et al. (2) . This is an in-frame deletion in which 37 amino acids (residues 174–210) are deleted in the putative ligand-binding domain (Fig. 2) . The protein predicted to be encoded by this variant hPXR mRNA, assuming there are no other alterations in the mRNA, would be 397 amino acids, unlikely to bind ligand or have a markedly altered ligand profile compared to that of the "wild-type" hPXR (1) . This variant human hPXR mRNA has not been reported previously and is similar but not identical to the mouse PXR.2, which contains an in-frame 123-nucleotide deletion predicting a 41-amino acid deletion in a similar region of the ligand-binding domain (1) .

View larger version (57K): [in this window] [in a new window] [Download PPT slide]   Fig. 1.  Expression of hPXR mRNA and a variant hPXR mRNA in human breast cancer cell lines. Top, total RNA was extracted from six human breast cancer cell lines. Radiolabeled RT-PCR products using primers for human PXR and 35 cycles of PCR, separated by 6% PAGE containing 7 M urea, are shown. The hPXR.1 or wild-type product is 442 bp. The hPXR.2 or variant product is 331 bp. Bottom, amplification of GAPDH in the same six human breast cancer cell lines. The GAPDH PCR product was visualized by ethidium bromide staining of agarose gels.

View larger version (10K): [in this window] [in a new window] [Download PPT slide]   Fig. 2.  Diagrammatic representation of the protein predicted to be encoded by the variant hPXR mRNA. hPXR.1 represents the wild-type human PXR (2) . hPXR.2 represents the deleted PXR variant. Numbers represent the amino acid residues. DBD, DNA-binding domain; LBD, ligand-binding domain.

View larger version (56K): [in this window] [in a new window] [Download PPT slide]   Fig. 3.  Expression of hPXR mRNA and a variant hPXR mRNA in human breast tumor biopsies and their matched normal adjacent breast tissues. Top, total RNA was extracted from human breast cancer biopsy samples (Lanes T) and their matched adjacent normal breast tissues (Lanes N). Radiolabeled RT-PCR products using primers for human PXR and 35 cycles of PCR, separated on 6% PAGE containing 7 M urea, are shown. The hPXR.1 or wild-type product is 442 bp. The hPXR.2 or variant product is 331 bp. Both ER+ and ER- tumors were analyzed. Bottom, amplification of GAPDH in the same human breast tissue samples. The GAPDH PCR product was visualized by ethidium bromide staining of agarose gels.

View larger version (38K): [in this window] [in a new window] [Download PPT slide]   Fig. 4.  Relationship of expression of hPXR-like mRNA to ER and PR status in human breast tumors. A, total RNA was extracted from human breast cancer biopsy samples of known ER (+ or -) and PR (+ or -) status, as defined by ligand-binding assays. Radiolabeled RT-PCR products using primers for human PXR and 35 cycles of PCR, separated on 6% PAGE containing 7 M urea, are shown. The hPXR.1 or wild-type product is 442 bp. The hPXR.2 or variant product is 331 bp. Bottom, amplification of GAPDH in the same human breast cancer biopsy samples. The GAPDH PCR product was visualized by ethidium bromide staining of agarose gels. B, relative PXR signals quantified as described in "Materials and Methods" are presented for ER- and ER+ breast tumors. The median of the values obtained in each group is indicated by a solid line.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The data presented here provide evidence that the novel nuclear orphan receptor hPXR is expressed in both normal and neoplastic human breast tissues. As yet, there are no available antibodies to the hPXR protein to complement this investigation. Recombinantly expressed hPXR protein has been shown to activate transcription of reporter genes through a response element conserved in the promoter of the CYP3A genes (1 , 2) , suggesting the possibility that hPXR might be a transcriptional regulator of CYP3A enzyme expression (2) . Because these CYP3A enzymes have also been found in human breast cancer tissues (6 , 7) , we hypothesized that hPXR/CYP3A-regulated pathways might play a role in human breast cancer.

The CYP3A enzymes, the expression of which is likely to be modulated, at least in part, by hPXR, are known to be involved in the metabolism of a wide range of xenobiotics, natural and synthetic steroids, and antisteroids, including tamoxifen and toremifene (3, 4, 5 , 12 , 13) . Our observation that hPXR is expressed in both normal and neoplastic breast tissue opens the possibility that local metabolism and the factors regulating local metabolism may have a role in the responsiveness of human breast cancers to endocrine therapies. Indeed, altered uptake and retention of tamoxifen and possible altered local metabolism have been suggested as possible mechanisms of tamoxifen resistance in some human breast cancers (14 , 15) . Also, the antiglucocorticoid/antiprogestin compound RU-486 was shown to be a relatively potent activator of hPXR (1) . RU-486 has shown some efficacy as an endocrine therapy in human breast cancer (16) ; therefore, the interaction of RU-486 with PXR in human breast tissues, both normal and neoplastic, might be important to assess with respect to drug resistance and/or drug interactions.

Although the natural ligand for hPXR is unknown, the observations that high concentrations of several natural hormones, e.g., pregnenolone and progesterone, and synthetic pregnenolone derivatives, such as pregnenolene 16-carbonitrile, can activate hPXR have led to its being named the pregnane X receptor (1) . It is unlikely that the concentrations required for any of these individual compounds that activate hPXR in vitro could be achieved in the circulation under physiological conditions; tissue accumulation levels and the possible additive effects of the various potential ligand activators of this receptor, which is activated by a wide spectrum of compounds, are unknown.

Our interest is in factors that could influence responsiveness to the so-called endocrine or hormonal therapies in human breast cancers, and we, therefore, investigated the relationship of hPXR expression to ER and PR status, which are known markers of treatment response to endocrine therapies and are also used as prognostic markers in human breast cancer (17) . We observed that, in human breast tumors, the expression of hPXR was inversely correlated with the expression of ER, suggesting that hPXR-mediated pathways might be more active in breast tumors which are less likely to respond to endocrine therapies. This remains to be tested in samples of breast tumors from patients with known responses to endocrine therapies in clinical trials.

We have also investigated whether altered expression of hPXR occurs between matched normal and neoplastic breast tissues from histopathologically defined tissue sections. In this study, we found no significant difference in hPXR expression between matched normal and neoplastic breast tissues. The ER status of these normal tissues was not determined; however, given that normal tissue is often ER- and ER+ cells are a minor component (18) and that the epithelial cell content among the typical relatively sparse ducts and lobular units found in normal tissue is lower than in tumor sections (13.5 ± 6.6% versus 40.4 ± 13.6%, respectively, in this study), these results suggest that average hPXR expression is, in fact, high in normal epithelia, which is consistent with the inverse relationship between ER status and hPXR seen in tumors. This interpretation suggests that hPXR is not significantly altered during tumorigenesis but may show changes in relation to altered differentiation and phenotype in tumors.

This is the first description of a human PXR variant mRNA that contains an in-frame deletion of 111 nucleotides corresponding to a deletion of nucleotides 823–933 of the wild-type hPXR mRNA and is most likely generated by an alternative splicing mechanism. This variant is similar but not identical to mouse PXR.2, which contains an in-frame 123-nucleotide deletion in a similar region of the ligand-binding domain (1) . The mouse PXR.2, compared to the mouse PXR.1, showed a markedly reduced profile with respect to the agents that could activate the wild-type receptor in transient transfection analyses (1) . It is possible that the human variant PXR may display a similar profile or may be unable to bind ligand. In this study, the presence or absence of this variant hPXR mRNA was not correlated with tumorigenesis or with ER/PR status.

In conclusion, we have identified the expression of human PXR mRNA and a hPXR variant mRNA in both normal and neoplastic human breast tissues. The expression of human PXR mRNA in breast tumors was inversely correlated with expression of ER, as determined by ligand binding assay. These data raise the possibility that hPXR may play a role in human breast tissues.

	ACKNOWLEDGMENTS

 
We thank Caroline Cumins-Leygue and Helen Bergen for laboratory assistance with the cell culture.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by grants from the Canadian Breast Cancer Research Initiative and the United States Army Medical Research and Materiel Command. The Manitoba Breast Tumor Bank is supported by funding from the NCIC. L. C. M. is a Medical Research Council of Canada Scientist, P. W. is a Medical Research Council of Canada Clinician-Scientist, and E. L. is a recipient of a United States Army Medical Research and Materiel Command Postdoctoral Fellowship.

² To whom requests for reprints should be addressed. Phone: (204) 789-3233; Fax: (204) 789-3900; E-mail:lcmurph{at}cc.umanitoba.ca

³ The abbreviations used are: CY3PA, cytochrome P450 monooxygenase 3A4; NCIC, National Cancer Institute of Canada; ER, estrogen receptor; PR, progesterone receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcription-PCR.

Received 2/23/99; revised 5/ 3/99; accepted 5/ 4/99.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. nKliewer S., Moore J., Wade L., Staudinger J., Watson M., Jones S., McKee D., Oliver B., Willson T., Zetterstrom R., Perlmann T., Lehmann J. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 92: 73-82, 1998.[Medline]
2. nLehmann J., McKee D., Watson M., Willson T., Moore J., Kliewer S. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 102: 1016-1023, 1998.[Medline]
3. nMani C., Gelboin H., Park S., Pearce R., Parkinson A., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. 1. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21: 645-656, 1993.[Abstract]
4. nBerthou F., Dreano Y., Belloc C., Kangas L., Gautier J-C., Beaune P. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol., 47: 1883-1895, 1994.[Medline]
5. nMani C., Pearce R., Parkinson A., Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis (Lond.), 15: 2715-2720, 1994.[Abstract/Free Full Text]
6. nHuang Z., Fasco M., Figge H., Keyomarsi K., Kaminsky L. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Dispos., 24: 899-905, 1996.[Abstract]
7. nSmith G., Harrison D., East N., Rae F., Wolf H., Wolf C. Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts. Br. J. Cancer, 68: 57-63, 1993.[Medline]
8. nHiller T., Snell L., Watson P. Microdissection/RT-PCR analysis of gene expression. Biotechniques, 21: 38-44, 1996.[Medline]
9. nMurphy L., Lee-Wing M., Goldenberg G., Shiu R. Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo: correlation with steroid receptor status. Cancer Res., 47: 4160-4164, 1987.[Abstract/Free Full Text]
10. nMurphy L. C., Dotzlaw H. Regulation of transforming growth factor alpha and transforming growth factor ß messenger ribonucleic acid abundance in T-47D, human breast cancer cells. Mol. Endocrinol., 3: 611-617, 1989.[Medline]
11. nDotzlaw H., Leygue E., Watson P., Murphy L. Expression of estrogen receptor-ß in human breast tumors. J. Clin. Endocrinol. Metab., 82: 2371-2374, 1997.[Abstract/Free Full Text]
12. nNebert D., Gonzalez F. P450 genes: structure, evolution and regulation. Annu. Rev. Biochem., 56: 945-993, 1987.[Medline]
13. nJuchau M. Substrate specificities and functions of the P450 cytochromes. Life Sci., 47: 2385-2394, 1990.[Medline]
14. nOsborne C., Coronado E., Allred D., Wiebe V., DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl. Cancer Inst., 83: 1477-1482, 1991.[Abstract/Free Full Text]
15. nOsborne C., Wiebe V., McGuire W., Ciocca D., DeGregorio M. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen resistant tumors from breast cancer patients. J. Clin. Oncol., 10: 304-310, 1992.[Abstract]
16. nGoldberg J., Plescia M., Anastasio G. Mifepristone (RU 486): current knowledge and future prospects. Arch. Fam. Med., 7: 219-222, 1998.[Abstract/Free Full Text]
17. nRavdin P., Green S., Dorr T., McGuire W., Fabian C., Pugh R., Carter R., Rivkin S., Borst J., Belt R., Metch B., Osborne C. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol., 10: 1284-1291, 1992.[Abstract/Free Full Text]
18. nPetersen O. Frequency and distribution of estrogen receptor positive cells in normal non-lactating human breast. Cancer Res., 47: 5748-5751, 1987.[Abstract/Free Full Text]

This article has been cited by other articles:

				L. M. Tompkins, T. L. Sit, and A. D. Wallace Unique Transcription Start Sites and Distinct Promoter Regions Differentiate the Pregnane X Receptor (PXR) Isoforms PXR 1 and PXR 2 Drug Metab. Dispos., May 1, 2008; 36(5): 923 - 929. [Abstract] [Full Text] [PDF]

				S. Takagi, M. Nakajima, T. Mohri, and T. Yokoi Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4 J. Biol. Chem., April 11, 2008; 283(15): 9674 - 9680. [Abstract] [Full Text] [PDF]

				R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr P-glycoprotein: So Many Ways to Turn It On J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378. [Abstract] [Full Text] [PDF]

				Y. Chen, Y. Tang, M.-T. Wang, S. Zeng, and D. Nie Human Pregnane X Receptor and Resistance to Chemotherapy in Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10361 - 10367. [Abstract] [Full Text] [PDF]

				K. A. Hagedorn, C.-L. Cooke, J. R. Falck, B. F. Mitchell, and S. T. Davidge Regulation of Vascular Tone During Pregnancy: A Novel Role for the Pregnane X Receptor Hypertension, February 1, 2007; 49(2): 328 - 333. [Abstract] [Full Text] [PDF]

				D. D. Moore, S. Kato, W. Xie, D. J. Mangelsdorf, D. R. Schmidt, R. Xiao, and S. A. Kliewer International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor Pharmacol. Rev., December 1, 2006; 58(4): 742 - 759. [Abstract] [Full Text] [PDF]

				P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. J. Clin. Pharmacol., November 1, 2006; 46(11): 1356 - 1369. [Abstract] [Full Text] [PDF]

				A. Takeshita, K. Inagaki, J. Igarashi-Migitaka, Y. Ozawa, and N. Koibuchi The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J. Endocrinol., September 1, 2006; 190(3): 897 - 902. [Abstract] [Full Text] [PDF]

				Y. Miki, T. Suzuki, K. Kitada, N. Yabuki, R. Shibuya, T. Moriya, T. Ishida, N. Ohuchi, B. Blumberg, and H. Sasano Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma Cancer Res., January 1, 2006; 66(1): 535 - 542. [Abstract] [Full Text] [PDF]

				J. Orans, D. G. Teotico, and M. R. Redinbo The Nuclear Xenobiotic Receptor Pregnane X Receptor: Recent Insights and New Challenges Mol. Endocrinol., December 1, 2005; 19(12): 2891 - 2900. [Abstract] [Full Text] [PDF]

				S. Mani, H. Huang, S. Sundarababu, W. Liu, G. Kalpana, A. B. Smith, and S. B. Horwitz Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents Clin. Cancer Res., September 1, 2005; 11(17): 6359 - 6369. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				D. Gardner-Stephen, J.-M. Heydel, A. Goyal, Y. Lu, W. Xie, T. Lindblom, P. Mackenzie, and A. Radominska-Pandya HUMAN PXR VARIANTS AND THEIR DIFFERENTIAL EFFECTS ON THE REGULATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE GENE EXPRESSION Drug Metab. Dispos., March 1, 2004; 32(3): 340 - 347. [Abstract] [Full Text] [PDF]

				H. Jinno, T. Tanaka-Kagawa, N. Hanioka, S. Ishida, M. Saeki, A. Soyama, M. Itoda, T. Nishimura, Y. Saito, S. Ozawa, et al. Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver Mol. Pharmacol., March 1, 2004; 65(3): 496 - 502. [Abstract] [Full Text] [PDF]

				C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF]

				M. M. Tabb, A. Sun, C. Zhou, F. Grun, J. Errandi, K. Romero, H. Pham, S. Inoue, S. Mallick, M. Lin, et al. Vitamin K2 Regulation of Bone Homeostasis Is Mediated by the Steroid and Xenobiotic Receptor SXR J. Biol. Chem., November 7, 2003; 278(45): 43919 - 43927. [Abstract] [Full Text] [PDF]

				S. Teng, V. Jekerle, and M. Piquette-Miller INDUCTION OF ABCC3 (MRP3) BY PREGNANE X RECEPTOR ACTIVATORS Drug Metab. Dispos., November 1, 2003; 31(11): 1296 - 1299. [Abstract] [Full Text] [PDF]

				H. Masuyama, Y. Hiramatsu, J.-i. Kodama, and T. Kudo Expression and Potential Roles of Pregnane X Receptor in Endometrial Cancer J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4446 - 4454. [Abstract] [Full Text] [PDF]

				S. S. Auerbach, R. Ramsden, M. A. Stoner, C. Verlinde, C. Hassett, and C. J. Omiecinski Alternatively spliced isoforms of the human constitutive androstane receptor Nucleic Acids Res., June 15, 2003; 31(12): 3194 - 3207. [Abstract] [Full Text] [PDF]

				A. Westlind-Johnsson, S. Malmebo, A. Johansson, C. Otter, T. B. Andersson, I. Johansson, R. J. Edwards, A. R. Boobis, and M. Ingelman-Sundberg COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM Drug Metab. Dispos., June 1, 2003; 31(6): 755 - 761. [Abstract] [Full Text] [PDF]

				T. K. H. Chang, S. M. Bandiera, and J. Chen Constitutive Androstane Receptor and Pregnane X Receptor Gene Expression in Human Liver: Interindividual Variability and Correlation with CYP2B6 mRNA Levels Drug Metab. Dispos., January 1, 2003; 31(1): 7 - 10. [Abstract] [Full Text] [PDF]

				J. Sonoda, W. Xie, J. M. Rosenfeld, J. L. Barwick, P. S. Guzelian, and R. M. Evans Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR) PNAS, October 15, 2002; 99(21): 13801 - 13806. [Abstract] [Full Text] [PDF]

				S. A. Kliewer, B. Goodwin, and T. M. Willson The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism Endocr. Rev., October 1, 2002; 23(5): 687 - 702. [Abstract] [Full Text] [PDF]

				I. Koch, R. Weil, R. Wolbold, J. Brockmoller, E. Hustert, O. Burk, A. Nuessler, P. Neuhaus, M. Eichelbaum, U. Zanger, et al. Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA Drug Metab. Dispos., October 1, 2002; 30(10): 1108 - 1114. [Abstract] [Full Text] [PDF]

				K. E. Thummel, C. Brimer, K. Yasuda, J. Thottassery, T. Senn, Y. Lin, H. Ishizuka, E. Kharasch, J. Schuetz, and E. Schuetz Transcriptional Control of Intestinal Cytochrome P-4503A by 1alpha ,25-Dihydroxy Vitamin D3 Mol. Pharmacol., December 1, 2001; 60(6): 1399 - 1406. [Abstract] [Full Text] [PDF]

				E. Hustert, A. Zibat, E. Presecan-Siedel, R. Eiselt, R. Mueller, C. Fu{beta}, I. Brehm, U. Brinkmann, M. Eichelbaum, L. Wojnowski, et al. Natural Protein Variants of Pregnane X Receptor with Altered Transactivation Activity Toward CYP3A4 Drug Metab. Dispos., November 1, 2001; 29(11): 1454 - 1459. [Abstract] [Full Text] [PDF]

				W. Xie, J. L. Barwick, C. M. Simon, A. M. Pierce, S. Safe, B. Blumberg, P. S. Guzelian, and R. M. Evans Reciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR Genes & Dev., December 1, 2000; 14(23): 3014 - 3023. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dotzlaw, H. Articles by C. Murphy, L. Search for Related Content PubMed PubMed Citation Articles by Dotzlaw, H. Articles by C. Murphy, L.